Home › Trials › NCT05090566

Combining Elranatamab with Other Cancer Treatments for Multiple Myeloma

A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA

Phase 2 Interventional Pfizer · NCT05090566

This study is testing if combining a new cancer drug called elranatamab with other treatments can help people with tough-to-treat multiple myeloma feel better.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment120 (estimated)
Ages18 Years and up
SexAll
SponsorPfizer Industry-sponsored
Drugs / interventionselranatamab
Locations29 sites (Gilbert, Arizona and 28 other locations)
Trial IDNCT05090566 on ClinicalTrials.gov

What this trial studies

This study aims to evaluate the effectiveness and determine the recommended dose of elranatamab when used alongside other anti-cancer therapies in patients with multiple myeloma. Participants must have relapsed or refractory multiple myeloma and have undergone at least three prior lines of therapy. The study will assess clinical benefits and safety profiles of the combination treatments, which include elranatamab with nirogacestat and elranatamab with lenalidomide and dexamethasone.

Who should consider this trial

Good fit: Ideal candidates are adults with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy.

Not a fit: Patients with active plasma cell leukemia, amyloidosis, or those who have had a stem cell transplant within the last 12 weeks may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new effective treatment option for patients with difficult-to-treat multiple myeloma.

How similar studies have performed: Other studies have shown promise with similar combination therapies in multiple myeloma, suggesting potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy
* Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody
* Measurable disease defined by at least one of the following:

  1. Serum M-protein \>/= 0.5 g/dL by SPEP
  2. Urinary M-protein excretion \>/= 200 mg/24 hours by UPEP
  3. Serum immunoglobulin FLC \>/= 10 mg/dL (\>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio
* ECOG performance status 0 -1
* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade \</= 1

Exclusion Criteria:

* Active plasma cell leukemia
* Amyloidosis
* Stem cell transplant with 12 weeks prior to enrollment, or active GVHD
* POEMS syndrome
* Any active uncontrolled bacterial, fungal, or viral infection
* Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment
* Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer)
* Sub-Study A Only: Previous treatment with BCMA bispecific antibody
* Sub-Study B Only: Previous treatment with BCMA directed therapy

Where this trial is running

Gilbert, Arizona and 28 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Multiple MyelomaPF-06863135, Multiple Myeloma, BCMA, elranatamab, bispecific antibody, MagnetisMM-4
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.